VALDOXAN® GRANTED MARKETING AUTHORISATION FOR THE TREATMENT OF MAJOR DEPRESSIVE EPISODES IN EUROPE

Paris, France; 24 February, 2009 – The European Commission has granted marketing authorisation for Servier’s Valdoxan® /Thymanax® (agomelatine), the first melatonergic antidepressant for the treatment of adult patients with major depressive episodes.